pharma · Chronic Lymphocytic Leukemia (CLL) · Chronic Lymphocytic Leukemia · APVO
Aptevo Therapeutics
Aptevo Therapeutics is a pharma organization headquartered in Seattle, USA. It trades on NYSE under ticker APVO. Primary therapeutic focus areas include Chronic Lymphocytic Leukemia (CLL), Chronic Lymphocytic Leukemia, S
Seattle, USA HQ
2016 Founded
54 Employees
Public company Type
APVO · NYSE Ticker
Company details
- Status
- Public
- HQ
- Seattle, USA
- Founded
- 2016
- Employees
- 54
- Programs
- 9
- Drugs
- 4
- Patents
- 13
TRU-016 (anti-CD37 protein therapeutic)
Phase 1 · small molecule · Chronic Lymphocytic Leukemia (CLL)
TRU-016 (anti-CD37 protein therapeutic) for Chronic Lymphocytic Leukemia (CLL) is a Phase 1 program (small_molecule) at Aptevo Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code 16007
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Aptevo Therapeutics
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Chronic Lymphocytic Leukemia (CLL)
- Status
- completed
- Trials
- 1